hepatitis : Health & Medical
Recipients of OLT for hepatitis C invariably develop recurrent disease. The risk factors for death and retransplantation following the development of cirrhosis from HCV are unclear.
Do genetic polymorphisms affect the pharmacokinetics of tacrolimus in patients with ulcerative colitis, and do they determine whether or not a patient will go into remission?
Results of this study may serve as a guide to optimal treatment duration in certain patient groups.
What is the connection between coffee consumption and the potential risk for hepatocellular carcinoma? Does it offer a protective effect?
What types of drugs in combination work best in hepatitis C? This new study explores the options.
Is the tyrosine kinase inhibitor, sorafenib, an effective treatment in patients with advanced hepatocellular carcinoma refractory to chemotherapy?
HCV genotype 4 infection is progressing in Europe, where epidemiology and sustained virologic response seem to be different than in the Middle East.
What are the effects of persistently detectable hepatitis B virus DNA on hepatocellular carcinoma recurrence? Find out why timing matters most.
This article looks at the pathophysiology of various types of cholestasis, with a focus on the genetic determinants.
Should hyaluronic acid be used when performing endoscopic mucosal resection to remove colorectal polyps?
Lab tests suggest over-the-counter antihistamine could offer alternative to pricey new drugs
What does the latest research tell us about the connection between H. pylori disease and the potential to develop HCV-related chronic liver disease and hepatocellular carcinoma? This new study looks at the possible link.